Search Results - Jordan, Justin
- Showing 1 - 20 results of 42
- Go to Next Page
-
1
-
2
-
3
-
4
ACTR-36. A SINGLE ARM PHASE 2 STUDY OF THE DUAL mTORC1/mTORC2 INHIBITOR VISTUSERTIB PROVIDED ON AN INTERMITTENT SCHEDULE FOR NEUROFIBROMATOSIS 2 PATIENTS WITH PROGRESSIVE OR SYMPTO... by Plotkin, Scott, Jordan, Justin, Beauchamp, Roberta, Muzikansky, Alona, Stemmer-Rachamimov, Anat, Ramesh, Vijaya
Published 2018Text -
5
-
6
NIMG-66. LONG-TERM FOLLOW-UP OF NEUROFIBROMATOSIS TYPE 1 PATIENTS USING WHOLE-BODY MRI DEMONSTRATES DYNAMIC CHANGES IN INTERNAL NEUROFIBROMA SIZE by Ly, Ina, Thalheimer, Raquel, Cai, Wenli, Bredella, Miriam, Merker, Vanessa, Plotkin, Scott, Jordan, Justin
Published 2019Text -
7
-
8
Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schw... by Merker, Vanessa L., Dai, Annie, Radtke, Heather B., Knight, Pamela, Jordan, Justin T., Plotkin, Scott R.
Published 2018Text -
9
Effective Provider-Patient Communication of a Rare Disease Diagnosis: A Qualitative Study of People Diagnosed with Schwannomatosis by Merker, Vanessa L., Plotkin, Scott R., Charns, Martin P., Meterko, Mark, Jordan, Justin T., Elwy, A. Rani
Published 2020Text -
10
mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition by Beauchamp, Roberta L., Erdin, Serkan, Witt, Luke, Jordan, Justin T., Plotkin, Scott R., Gusella, James F., Ramesh, Vijaya
Published 2020Text -
11
-
12
Cost-effectiveness of IDH testing in diffuse gliomas according to the 2016 WHO classification of tumors of the central nervous system recommendations by DeWitt, John C, Jordan, Justin T, Frosch, Matthew P, Samore, Wesley R, Iafrate, A John, Louis, David N, Lennerz, Jochen K
Published 2017Text -
13
Correlation between NF1 genotype and imaging phenotype on whole-body MRI: NF1 radiogenomics by Liu, Yunpeng, Jordan, Justin T., Bredella, Miriam A., Erdin, Serkan, Walker, James A., Vangel, Mark, Harris, Gordon J., Plotkin, Scott R., Cai, Wenli
Published 2020Text -
14
NIMG-07. LONG-TERM FOLLOW-UP OF SCHWANNOMA GROWTH BEHAVIOR IN ADULT NEUROFIBROMATOSIS TYPE 2 AND SCHWANNOMATOSIS PATIENTS USING WHOLE-BODY MRI by Ly, Ina, Thalheimer, Raquel, Cai, Wenli, Bredella, Miriam, Muzikansky, Alona, Merker, Vanessa, Herr, Hamilton, Da, Jennifer, Harris, Gordon, Plotkin, Scott, Jordan, Justin
Published 2020Text -
15
-
16
DINs: Deep Interactive Networks for Neurofibroma Segmentation in Neurofibromatosis Type 1 on Whole-Body MRI by Zhang, Jian-Wei, Chen, Wei, Ly, K. Ina, Zhang, Xubin, Yan, Fan, Jordan, Justin, Harris, Gordon, Plotkin, Scott, Hao, Pengyi, Cai, Wenli
Published 2022Text -
17
The Use of MEK Inhibitors in Neurofibromatosis Type 1–Associated Tumors and Management of Toxicities by Klesse, Laura J., Jordan, Justin T., Radtke, Heather B., Rosser, Tena, Schorry, Elizabeth, Ullrich, Nicole, Viskochil, David, Knight, Pamela, Plotkin, Scott R., Yohay, Kaleb
Published 2020Text -
18
-
19
Mind-Body Treatment for International English-Speaking Adults With Neurofibromatosis via Live Videoconferencing: Protocol for a Single-Blind Randomized Controlled Trial by Vranceanu, Ana-Maria, Zale, Emily L, Funes, Christopher J, Macklin, Eric A, McCurley, Jessica, Park, Elyse R, Jordan, Justin T, Lin, Ann, Plotkin, Scott R
Published 2018Text -
20
Temozolomide therapy for aggressive functioning pituitary adenomas refractory to surgery and radiation: a case series by Jordan, Justin T, Miller, Julie J, Cushing, Tucker, Seijo, Marlon, Batchelor, Tracy T, Arrillaga-Romany, Isabel C, Shih, Helen A, Nachtigall, Lisa B, Loeffler, Jay S, Dietrich, Jorg
Published 2018Text